Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord acellular suspension
- Development stage
- Unknown
- Lead developer
- Vitti Labs
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intraarticular
01
Overview
Umbilical cord acellular suspension (UCAS) is a regenerative biologic product derived from human umbilical cord tissue, processed to remove all cellular components while retaining a high concentration of bioactive molecules. Developed primarily by Vitti Labs, UCAS contains a complex milieu of growth factors (such as VEGF, PDGF, and TGF-β), anti-inflammatory cytokines (including IL-10 and IL-1ra), hyaluronic acid, and extracellular matrix proteins. Its mechanism of action involves modulating the immune response, reducing pro-inflammatory signaling, and providing a scaffold and signaling environment conducive to endogenous tissue repair and regeneration. It is typically administered via local injection or intravenous infusion and has been investigated in clinical trials for conditions characterized by severe inflammation or tissue degradation, such as COVID-19-related acute respiratory distress syndrome (ARDS) and knee osteoarthritis.
- Brand names
- UCAS
- Other names
- umbilical cord acellular suspensionUCAS
02
Targets
PDGFR (PDGFR family)VEGFR (VEGFR family)TGFBR (TGF-beta receptor)IL-1R (Interleukin-1 receptor type 1 (IL-1R1))IL10RA (Interleukin-10 Receptor)
Beyond the preview
Go deeper on umbilical cord acellular suspension.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord acellular suspension.